Esperion Therapeutics (NASDAQ:ESPR) Sets New 1-Year High at $76.98

Share on StockTwits

Esperion Therapeutics Inc (NASDAQ:ESPR) reached a new 52-week high on Thursday . The company traded as high as $76.98 and last traded at $72.61, with a volume of 35021 shares changing hands. The stock had previously closed at $70.11.

A number of analysts recently weighed in on the company. Chardan Capital restated a “hold” rating and issued a $65.00 price objective on shares of Esperion Therapeutics in a report on Friday, January 31st. ValuEngine downgraded Esperion Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, January 3rd. BidaskClub upgraded Esperion Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday. Citigroup downgraded Esperion Therapeutics from a “buy” rating to a “neutral” rating and increased their price objective for the company from $73.00 to $82.00 in a report on Friday. Finally, Cowen restated a “buy” rating on shares of Esperion Therapeutics in a report on Wednesday, November 6th. Six research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $68.00.

The company has a quick ratio of 4.41, a current ratio of 4.41 and a debt-to-equity ratio of 0.01. The firm has a market cap of $1.93 billion, a P/E ratio of -19.05 and a beta of 2.13. The stock’s 50-day simple moving average is $58.70 and its 200 day simple moving average is $45.77.

In other news, major shareholder Target N. V. Biotech purchased 20,000 shares of the business’s stock in a transaction on Thursday, January 23rd. The shares were acquired at an average price of $51.84 per share, with a total value of $1,036,800.00. Following the completion of the transaction, the insider now owns 3,747,964 shares of the company’s stock, valued at approximately $194,294,453.76. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 7.70% of the company’s stock.

A number of institutional investors and hedge funds have recently modified their holdings of the business. Tower Research Capital LLC TRC bought a new position in shares of Esperion Therapeutics during the 3rd quarter worth about $42,000. Tower Research Capital LLC TRC boosted its position in shares of Esperion Therapeutics by 21.2% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,361 shares of the biopharmaceutical company’s stock worth $81,000 after purchasing an additional 238 shares in the last quarter. Ancora Advisors LLC bought a new position in shares of Esperion Therapeutics during the 4th quarter worth about $134,000. Royal Bank of Canada boosted its position in shares of Esperion Therapeutics by 38.1% during the 2nd quarter. Royal Bank of Canada now owns 2,938 shares of the biopharmaceutical company’s stock worth $137,000 after purchasing an additional 811 shares in the last quarter. Finally, Marshall Wace LLP bought a new position in shares of Esperion Therapeutics during the 1st quarter worth about $186,000. 98.71% of the stock is currently owned by institutional investors and hedge funds.

About Esperion Therapeutics (NASDAQ:ESPR)

Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.

Further Reading: Stock Portfolio Tracker

Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Zacks Investment Research Downgrades Aramark  to Hold
Zacks Investment Research Downgrades Aramark to Hold
Brokerages Set Andersons Inc  PT at $21.50
Brokerages Set Andersons Inc PT at $21.50
Union Bankshares Corporation  Receives $39.50 Average Price Target from Analysts
Union Bankshares Corporation Receives $39.50 Average Price Target from Analysts
American National BankShares Inc  Receives $39.00 Consensus PT from Analysts
American National BankShares Inc Receives $39.00 Consensus PT from Analysts
United Bankshares, Inc.  Receives $40.38 Average Price Target from Brokerages
United Bankshares, Inc. Receives $40.38 Average Price Target from Brokerages
BankUnited  Expected to Announce Earnings of $0.72 Per Share
BankUnited Expected to Announce Earnings of $0.72 Per Share


 
© 2006-2020 Zolmax.